Anavex reports Q2 EPS (13c) vs. (13c) last year

“Anavex’s (AVXL) portfolio with non-invasive targeted upstream precision compounds continues to advance with special focus on Alzheimer’s disease and schizophrenia. We also continue to receive feedback from neurologists preferring convenient orally available and clinically meaningful Alzheimer’s disease treatment options, which can be accessed without logistical restrictions,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “Furthermore, we were excited to recently present open-label-extension data of blarcamesine for Alzheimer’s disease at AD/PD(TM) 2025, which confirmed continued clinically meaningful benefit for early Alzheimer’s disease patients.”